Camrelizumab in patients with advanced non-squamous non-small cell lung cancer: a cost-effective analysis in China.

Xie, Qian; Zheng, Hanrui; Su, Na; Li, Qiu

Xie, Qian; Zheng, Hanrui; Su, Na; Li, Qiu.

Affiliation

Xie Q; General Practice Ward/International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Zheng H; Department of Clinical Pharmacy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Su N; Department of Clinical Pharmacy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Li Q; Division of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China keythera@126.com.

BMJ Open ; 12(8): e061592, 2022 08 05.

Article in En | MEDLINE | ID: mdl-36194670

Subject(s)

Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Antibodies, Monoclonal, Humanized/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Cost-Benefit Analysis; Humans; Immunoglobulin G; Lung Neoplasms/pathology; Quality-Adjusted Life Years

Key words

CHEMOTHERAPY; HEALTH ECONOMICS; Health economics; Respiratory tract tumours

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Health_economic_evaluation Aspects: Patient_preference Limits: Humans Language: En Journal: BMJ Open Year: 2022 Document type: Article Affiliation country: China

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google